Milani A, Ciammella A M, Rossi L
Institute of Medical Pathology, Università Cattolica del Sacro Cuore, Rome, Italy.
Eur J Gastroenterol Hepatol. 1995 Aug;7(8):763-7.
To evaluate the effects of acute (60 mg intravenous bolus) and protracted (75 mg per day orally for 1 week) frusemide administration on ascites volume, free-water peritoneal clearance (FWPC), intra-abdominal pressure (IAP) and body weight in 30 decompensated cirrhotic patients.
Individual ascites volume and FWPC were estimated by means of a previously validated methylene-blue dilution test.
All the investigated parameters showed a significant reduction after the protracted diuretic treatment (ascites volume 9.0 +/- 1.0 to 4.9 +/- 0.61, P < 0.001; FWPC 99.8 +/- 6.7 to 76.2 +/- 6.6 ml/min, P < 0.001; IAP 17.0 +/- 1.5 to 11.3 +/- 0.8 cmH2O, P < 0.001; body weight 75.2 +/- 1.9 to 66.3 +/- 1.8 kg, P < 0.001). A significant FWPC reduction (89.5 +/- 14.6 to 68.8 +/- 12.1 ml/min, P < 0.02) was also observed after the acute frusemide administration in the absence of any appreciable modifications to ascites volumes and IAP.
Frusemide treatment appears to be able to exert a direct significant effect on FWPC, which does not appear to be mediated by ascites volume or IAP modifications.
评估急性（静脉推注60毫克）和长期（每日口服75毫克，持续1周）给予呋塞米对30例失代偿期肝硬化患者腹水体积、游离水腹膜清除率（FWPC）、腹腔内压力（IAP）和体重的影响。
通过先前验证的亚甲蓝稀释试验估算个体腹水体积和FWPC。
长期利尿治疗后，所有研究参数均显著降低（腹水体积从9.0±1.0降至4.9±0.61，P<0.001；FWPC从99.8±6.7降至76.2±6.6毫升/分钟，P<0.001；IAP从17.0±1.5降至11.3±0.8厘米水柱，P<0.001；体重从75.2±1.9降至66.3±1.8千克，P<0.001）。急性给予呋塞米后，在腹水体积和IAP无明显改变的情况下，FWPC也显著降低（从89.5±14.6降至68.8±12.1毫升/分钟，P<0.02）。
呋塞米治疗似乎能够对FWPC产生直接显著影响，这种影响似乎不是由腹水体积或IAP的改变介导的。
